Thumbs-down from FDA experts for Pfizer/Lilly's painkiller t...

After more than a decade of fraught clinical development it looks like the end of the line for Pfizer/Lilly painkiller tanezumab, which promised to be an alternative to addictive opioid pai

FDA worried about Pfizer/Lilly pain drug safety ahead of key...

After a long and troubled development the fate of Pfizer/Lilly’s tanezumab painkiller injection is in the balance ahead of a key meeting of advisers later this week. 

Kaia Health creates new 'front door' for MSK pain services

Kaia Health is adding to its offering for patients with musculoskeletal (MSK) pain via a partnership with Premium Partners to create a “front door” for patients in the US.

Lilly adds to pain pipeline with Asahi Kasei licensing deal

US drugmaker Eli Lilly – still waiting for an FDA decision on one non-opioid pain drug – has just added another to its pipeline via a licensing agreement with Japan’s Asahi Kasei worth up t

Satsuma pulped as acute migraine drug flunks phase 3 trial

Shares in California biotech Satsuma Pharma have lost three quarters of their value after lead drug STS01 failed to show any improvement over placebo in an acute migraine study.

FDA starts review of Pfizer, Lilly’s non-opioid painkiller